Compass Pathways to expedite launch of its experimental depression therapy [Yahoo! Finance]
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Yahoo! Finance
of its experimental psilocybin-based depression therapy by 9 to 12 months, sending its shares nearly 6% higher. Following a positive meeting with the U.S. Food and Drug Administration, Compass plans for a rolling submission, providing trial results as they are completed, and the agency to review them upon receipt. The usual process involves companies submitting its entire application at once. CONTEXT The experimental therapy, COMP360, is based on the psychedelic compound, psilocybin, and is designed as a short-term, episodic alternative to daily antidepressants. It is being tested in patients with treatment-resistant depression. In June, data from a late-stage study showed the therapy reduced the severity of depression symptoms, but fell short of market expectations. Wall Street analysts, however, said the data indicated that COMP360 might get approved. WHY IT'S IMPORTANT The fast-growing market for psychedelic-based treatments for psychiatric conditions could be worth u
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- Cybin Initiates At-The-Market Equity Program of up to US$100 MillionBusiness Wire
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
- KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq [Yahoo! Finance]Yahoo! Finance
- Cybin to Transfer U.S. Stock Exchange Listing to NasdaqBusiness Wire
CYBN
Earnings
- 11/14/25 - Miss
CYBN
Sec Filings
- 1/5/26 - Form 6-K
- 1/2/26 - Form CERT
- 1/2/26 - Form 8-A12B
- CYBN's page on the SEC website